Application of an active comparator-based benefit-risk Assessment in evaluating clinical trial design features of a new chemical entity using a Bayesian decision-theoretic framework.
2010-06
Loading...
View/Download File
Persistent link to this item
Statistics
View StatisticsJournal Title
Journal ISSN
Volume Title
Title
Application of an active comparator-based benefit-risk Assessment in evaluating clinical trial design features of a new chemical entity using a Bayesian decision-theoretic framework.
Authors
Published Date
2010-06
Publisher
Type
Thesis or Dissertation
Abstract
During the drug development process, drug candidates are screened for their efficacy and
toxicity. Dose selection is a crucial part of drug development and specifying the right
dose imparts pharmacological activity while minimizing side effects. Evaluation of the
benefit/risk ratio is typically done by examining the effect of a drug on efficacy and
safety endpoints. However, this comparison can be difficult when there are multiple
endpoints that are clinically and commercially relevant. A decision-based clinical utility
is proposed and evaluated to aid in dose selection. A dose is viable if it has higher
efficacy and lower toxicity than the values specified in multi-attribute decision criteria.
PD 0200390 is a ligand of the α2δ subunit of the voltage-gated calcium channel being
investigated for the treatment of primary insomnia and non-restorative sleep. Wake after
sleep onset and number of awakenings are the measures of sleep consolidation while ease
of awakening and morning behavior following wakefulness are the measures of residual
effects. The objective of this research is to select a dose that maximizes the probability of
a decision criterion characterized over safety and efficacy attributes. Data is obtained
from two phase II double blind, randomized, placebo controlled crossover studies in
subjects with primary insomnia. Dose response models are developed as hierarchical nonlinear
model using NONMEM® and WinBUGS®. A Sensitivity analysis is performed to
test the robustness of the selected dose with varying decision attributes.
Description
University of Minnesota Ph.D. dissertation. June 2010. Major: Social, Administrative, and Clinical Pharmacy. Advisor:Richard C. Brundage, Ph.D. 1 computer file (PDF); ix, 129 pages, appendix A. Ill. (some col.)
Related to
Replaces
License
Collections
Series/Report Number
Funding information
Isbn identifier
Doi identifier
Previously Published Citation
Suggested citation
Goel, Varun. (2010). Application of an active comparator-based benefit-risk Assessment in evaluating clinical trial design features of a new chemical entity using a Bayesian decision-theoretic framework.. Retrieved from the University Digital Conservancy, https://hdl.handle.net/11299/93902.
Content distributed via the University Digital Conservancy may be subject to additional license and use restrictions applied by the depositor. By using these files, users agree to the Terms of Use. Materials in the UDC may contain content that is disturbing and/or harmful. For more information, please see our statement on harmful content in digital repositories.